ClinicalTrials.gov
ClinicalTrials.gov Menu

Enhancing a High School Based Smoking Cessation Program

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01145001
Recruitment Status : Completed
First Posted : June 16, 2010
Results First Posted : October 19, 2016
Last Update Posted : December 29, 2016
Sponsor:
Collaborators:
National Institutes of Health (NIH)
National Institute on Drug Abuse (NIDA)
Information provided by (Responsible Party):
Yale University

Study Type: Interventional
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: Double (Participant, Care Provider);   Primary Purpose: Treatment
Condition: Nicotine Dependence
Interventions: Behavioral: Cognitive Behavioural Therapy
Behavioral: Contingency Management
Drug: Nicotine Transdermal Patch

  Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Active Nicotine Patch and Contingency Management

Subjects in this group will receive Contingency Management and active nicotine patch

Cognitive Behavioural Therapy: Weekly CBT for all subjects

Contingency Management: incentives given for abstinence based on urine analysis

Nicotine Transdermal Patch: 14mg ir 21mg doses based on weight and #cigs/day

Nicotine Patch With no Contingency Management

Subjects in this group will receive active nicotine patch without contingency management for abstinence

Cognitive Behavioural Therapy: Weekly CBT for all subjects

Nicotine Transdermal Patch: 14mg ir 21mg doses based on weight and #cigs/day

Placebo Patch and Contingency Management

Subjects in this group will receive a placebo transdermal patch and contingency management

Cognitive Behavioural Therapy: Weekly CBT for all subjects

Contingency Management: incentives given for abstinence based on urine analysis

Placebo Patch and no Contingency Management

Subjects in this group will receive a placebo patch and will not receive contingency management

Cognitive Behavioural Therapy: Weekly CBT for all subjects


Participant Flow:   Overall Study
    Active Nicotine Patch and Contingency Management   Nicotine Patch With no Contingency Management   Placebo Patch and Contingency Management   Placebo Patch and no Contingency Management
STARTED   36   37   44   37 
COMPLETED   28   31   39   31 
NOT COMPLETED   8   6   5   6 



  Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Active Nicotine Patch and Contingency Management

Subjects in this group will receive Contingency Management and active nicotine patch

Cognitive Behavioural Therapy: Weekly CBT for all subjects

Contingency Management: incentives given for abstinence based on urine analysis

Nicotine Transdermal Patch: 14mg ir 21mg doses based on weight and #cigs/day

Nicotine Patch With no Contingency Management

Subjects in this group will receive active nicotine patch without contingency management for abstinence

Cognitive Behavioural Therapy: Weekly CBT for all subjects

Nicotine Transdermal Patch: 14mg ir 21mg doses based on weight and #cigs/day

Placebo Patch and Contingency Management

Subjects in this group will receive a placebo transdermal patch and contingency management

Cognitive Behavioural Therapy: Weekly CBT for all subjects

Contingency Management: incentives given for abstinence based on urine analysis

Placebo Patch and no Contingency Management

Subjects in this group will receive a placebo patch and will not receive contingency management

Cognitive Behavioural Therapy: Weekly CBT for all subjects

Total Total of all reporting groups

Baseline Measures
   Active Nicotine Patch and Contingency Management   Nicotine Patch With no Contingency Management   Placebo Patch and Contingency Management   Placebo Patch and no Contingency Management   Total 
Overall Participants Analyzed 
[Units: Participants]
 36   37   44   37   154 
Age 
[Units: Participants]
Count of Participants
         
<=18 years      34  94.4%      36  97.3%      42  95.5%      37 100.0%      149  96.8% 
Between 18 and 65 years      2   5.6%      1   2.7%      2   4.5%      0   0.0%      5   3.2% 
>=65 years      0   0.0%      0   0.0%      0   0.0%      0   0.0%      0   0.0% 
Age 
[Units: Years]
Mean (Standard Deviation)
 16.53  (1.276)   16.62  (1.233)   16.66  (1.01)   16.30  (1.151)   16.53  (1.161) 
Gender 
[Units: Participants]
Count of Participants
         
Female      11  30.6%      14  37.8%      17  38.6%      17  45.9%      59  38.3% 
Male      25  69.4%      23  62.2%      27  61.4%      20  54.1%      95  61.7% 
Region of Enrollment 
[Units: Participants]
         
United States   36   37   44   37   154 


  Outcome Measures

1.  Primary:   Abstinence Rates at the End of Treatment   [ Time Frame: 6 weeks ]

2.  Secondary:   Continuous Abstinence During Treatment   [ Time Frame: 6 weeks ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information

Certain Agreements:  
All Principal Investigators ARE employed by the organization sponsoring the study.


Results Point of Contact:  
Name/Title: Dana Cavallo, Assistant Professor
Organization: Yale University
phone: 2039747607
e-mail: dana.cavallo@yale.edu



Responsible Party: Yale University
ClinicalTrials.gov Identifier: NCT01145001     History of Changes
Other Study ID Numbers: 020718574
P50DA009241-17 ( U.S. NIH Grant/Contract )
First Submitted: June 14, 2010
First Posted: June 16, 2010
Results First Submitted: August 24, 2016
Results First Posted: October 19, 2016
Last Update Posted: December 29, 2016